We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Clovis Oncology

News List

Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board americanpharmaceuticalreview
June 15, 2017
Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery...
Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock firstwordpharma
January 05, 2017
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.00 per share, before underwriting discounts and commissions.

Previous page 1 2 Next page